{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T17:05:56Z","timestamp":1778346356348,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":2684,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5K-12 CA090625-09"],"award-info":[{"award-number":["5K-12 CA090625-09"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vanderbilt Clinical and Translational Science Award","award":["1 UL1 RR024975"],"award-info":[{"award-number":["1 UL1 RR024975"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.exphem.2014.10.009","type":"journal-article","created":{"date-parts":[[2014,10,28]],"date-time":"2014-10-28T03:21:06Z","timestamp":1414466466000},"page":"74-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Increased serum tumor necrosis factor \u03b1 levels in patients with lenalidomide-induced hypothyroidism"],"prefix":"10.1016","volume":"43","author":[{"given":"Wade T.","family":"Iams","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan L.","family":"Hames","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy P.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly B.","family":"Dahlman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahsa S.","family":"Talbott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristy L.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishitha M.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2014.10.009_bib1","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive nonHodgkin's lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2014.10.009_bib2","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell nonHodgkin's lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.exphem.2014.10.009_bib3","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1002\/cncr.26135","article-title":"Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype","volume":"117","author":"Hernandez-Ilizaliturri","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2014.10.009_bib4","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/leu.2013.95","article-title":"Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: A phase II clinical trial","volume":"27","author":"Wang","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2014.10.009_bib5","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.clml.2011.02.001","article-title":"Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 trial","volume":"11","author":"Zinzani","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.exphem.2014.10.009_bib6","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/jnci\/djr373","article-title":"Thyroid dysfunction from antineoplastic agents","volume":"103","author":"Hamnvik","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.exphem.2014.10.009_bib7","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s12185-013-1321-0","article-title":"Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma","volume":"97","author":"Harada","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1016\/j.exphem.2014.10.009_bib8","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-05-0577","article-title":"Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model","volume":"11","author":"Hernandez-Ilizaliturri","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2014.10.009_bib9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","article-title":"Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in\u00a0vivo","volume":"140","author":"Reddy","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2014.10.009_bib10","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0002-9343(01)01137-8","article-title":"Hypothyroidism in patients with multiple myeloma following treatment with thalidomide","volume":"112","author":"Badros","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.exphem.2014.10.009_bib11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/ajh.22008","article-title":"Thyroid abnormalities in patients treated with lenalidomide for hematologic malignancies: Results of a retrospective case review","volume":"86","author":"Figaro","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2014.10.009_bib12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/bmj.1.5062.84","article-title":"Antithyroid activity of N-phthalyl glutamic acid imide (K17)","volume":"1","author":"Murdoch","year":"1958","journal-title":"Br Med J"},{"key":"10.1016\/j.exphem.2014.10.009_bib13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1476-5381.1960.tb01217.x","article-title":"Pharmacological properties of thalidomide (alpha-phthalimido glutarimide), a new sedative hypnotic drug","volume":"15","author":"Somers","year":"1960","journal-title":"Br J Pharmacol Chemother"},{"key":"10.1016\/j.exphem.2014.10.009_bib14","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1089\/thy.2006.0294","article-title":"Transient thyroiditis after treatment with lenalidomide in a patient with metastatic renal cell carcinoma","volume":"17","author":"Stein","year":"2007","journal-title":"Thyroid"},{"key":"10.1016\/j.exphem.2014.10.009_bib15","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1080\/10428190701704613","article-title":"Lenalidomide-associated hypothyroidism","volume":"48","author":"Menon","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2014.10.009_bib16","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1210\/endo-125-4-1783","article-title":"Characterization of tumor necrosis factor-alpha receptors in human and rat thyroid cells and regulation of the receptors by thyrotropin","volume":"125","author":"Pang","year":"1989","journal-title":"Endocrinology"},{"key":"10.1016\/j.exphem.2014.10.009_bib17","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1210\/endo.136.3.7867596","article-title":"Tumor necrosis factor-alpha and interferon-gamma modulate gene expression of type I 5'-deiodinase, thyroid peroxidase, and thyroglobulin in FRTL-5 rat thyroid cells","volume":"136","author":"Tang","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/j.exphem.2014.10.009_bib18","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1365-2265.2002.01629.x","article-title":"Serum concentrations of tumour necrosis factor-alpha (TNF-alpha) and soluble TNF-alpha receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function","volume":"57","author":"Diez","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.exphem.2014.10.009_bib19","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2169\/internalmedicine.31.200","article-title":"Exacerbation of hypothyroidism following tumor necrosis factor-alpha infusion","volume":"31","author":"Miyakoshi","year":"1992","journal-title":"Intern Med"},{"key":"10.1016\/j.exphem.2014.10.009_bib20","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10067-007-0767-y","article-title":"Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism","volume":"27","author":"Sabugo","year":"2008","journal-title":"Clin Rheumatol"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X14007152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X14007152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:32:35Z","timestamp":1759566755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X14007152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0301472X14007152"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2014.10.009","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased serum tumor necrosis factor \u03b1 levels in patients with lenalidomide-induced hypothyroidism","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2014.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}